Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Novartis ships Excedrin Migraine; Perrigo will launch mini nicotine lozenges; Matrixx ups offer to buy ProPhase; Merck consolidates HQ in Summit, N.J.; NBTY expects at least 3% sales boost; FDA will hold risk communication meeting; more news In Brief.

You may also be interested in...



Perrigo Expands Smoking Cessation Line As Private Label Burns Up Category

Perrigo launches a private label version of Nicorette White Ice Mint Gum, a product it says generates nearly $80m in annual sales. Private label leads the smoking cessation category, with GSK the leading branded marketer.

Perrigo Expands Smoking Cessation Line As Private Label Burns Up Category

Perrigo launches a private label version of Nicorette White Ice Mint Gum, a product it says generates nearly $80m in annual sales. Private label leads the smoking cessation category, with GSK the leading branded marketer.

In Brief

ProPhase rebuffs revised Matrixx bid; “meth-deterring” Nexafed arrives in December; suits against Bayer, J&J and Pfizer dispute OTC expiration dates; Cantarell expands Nestle role; more news In Brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel